000661 长春高新
已收盘 06-18 15:00:00
资讯
新帖
简况
股市必读:长春高新(000661)6月18日董秘有最新回复
证券之星 · 02:35
股市必读:长春高新(000661)6月18日董秘有最新回复
每周股票复盘:长春高新(000661)现1723.58万元大宗交易
证券之星 · 06-21 02:11
每周股票复盘:长春高新(000661)现1723.58万元大宗交易
长春高新:结缔组织病相关间质性肺病相关适应症处于临床阶段
证券之星 · 06-18
长春高新:结缔组织病相关间质性肺病相关适应症处于临床阶段
长春高新:未发现存在违规变相协助大股东化债的情况
证券之星 · 06-18
长春高新:未发现存在违规变相协助大股东化债的情况
长春高新:酒店项目于2025年6—7月相继正式开业运营
证券之星 · 06-18
长春高新:酒店项目于2025年6—7月相继正式开业运营
长春高新:公司经营管理层努力提升经营质量
证券之星 · 06-18
长春高新:公司经营管理层努力提升经营质量
6月15日长春高新现1723.58万元大宗交易
证券之星 · 06-15
6月15日长春高新现1723.58万元大宗交易
长春高新最新公告:子公司注射用GenSci136获临床试验批准
证券之星 · 06-10
长春高新最新公告:子公司注射用GenSci136获临床试验批准
长春高新:系统性推进市值管理工作
证券之星 · 06-10
长春高新:系统性推进市值管理工作
长春高新:公司全力聚焦医药创新与主业发展
证券之星 · 06-10
长春高新:公司全力聚焦医药创新与主业发展
长春高新:产品临床试验获批相关公告是公司为了响应投资者所提出的希望公司持续提升信息披露透明度、增强投资者对于公司在研管线等情况了解的诉求进行的信息披露
证券之星 · 06-10
长春高新:产品临床试验获批相关公告是公司为了响应投资者所提出的希望公司持续提升信息披露透明度、增强投资者对于公司在研管线等情况了解的诉求进行的信息披露
长春高新:公司正处于从单一爆品向多元化创新的研发转型阵痛期
证券之星 · 06-05
长春高新:公司正处于从单一爆品向多元化创新的研发转型阵痛期
长春高新:公司此前向港交所提交的 H 股发行上市申请材料(A1 申请表)已超过港交所规定的六个月申报有效期
证券之星 · 06-05
长春高新:公司此前向港交所提交的 H 股发行上市申请材料(A1 申请表)已超过港交所规定的六个月申报有效期
长春高新:公司长期坚持合规为先的营销管理原则
证券之星 · 06-05
长春高新:公司长期坚持合规为先的营销管理原则
长春高新:相关股东自持有公司股份以来并未减持过公司股份
证券之星 · 06-04
长春高新:相关股东自持有公司股份以来并未减持过公司股份
长春高新:公司管理团队涵盖医药、企管、财务、法务、金融等多元专业背景
证券之星 · 06-04
长春高新:公司管理团队涵盖医药、企管、财务、法务、金融等多元专业背景
长春高新:公司相关费用的投入本质都是构建多元管线的必要投资
证券之星 · 06-04
长春高新:公司相关费用的投入本质都是构建多元管线的必要投资
长春高新:研发资金主要投向技术平台建设、临床阶段产品开发、早期管线布局等核心方向
证券之星 · 06-04
长春高新:研发资金主要投向技术平台建设、临床阶段产品开发、早期管线布局等核心方向
长春高新:研发持续落地多款新药、核心产品市占率领先
证券之星 · 06-04
长春高新:研发持续落地多款新药、核心产品市占率领先
长春高新(000661.SZ)子公司GenSci155注射液境内生产药品注册临床试验申请获得批准
智通财经 · 06-03
长春高新(000661.SZ)子公司GenSci155注射液境内生产药品注册临床试验申请获得批准
暂无数据
公司概况
公司名称:
长春高新技术产业(集团)股份有限公司
所属行业:
医药制造业
上市日期:
1996-12-18
主营业务:
长春高新技术产业(集团)股份有限公司的主营业务是生物制药及中成药的研发、生产和销售。公司的主要产品是注射用人生长激素、重组人生长激素注射液、注射用重组人促卵泡激素、重组人促卵泡激素注射液、醋酸曲普瑞林注射液、伏欣奇拜单抗、屋尘螨变应原制剂、醋酸甲地孕酮口服混悬液、口腔凝胶、水痘减毒活疫苗、带状疱疹减毒活疫苗、冻干鼻喷流感减毒活疫苗、鼻喷流感减毒活疫苗、银花泌炎灵片、清胃止痛微丸、血栓心脉宁片、疏清颗粒。
发行价格:
8.80
{"stockData":{"symbol":"000661","market":"SZ","secType":"STK","nameCN":"长春高新","latestPrice":64.1,"timestamp":1781766210000,"preClose":63.79,"halted":0,"volume":6809485,"delay":0,"changeRate":0.0049,"floatShares":400000000,"shares":408000000,"eps":-0.103,"marketStatus":"已收盘","change":0.31,"latestTime":"06-18 15:00:00","open":63.58,"high":65.6,"low":63.01,"amount":438000000,"amplitude":0.0406,"askPrice":64.12,"askSize":2,"bidPrice":64.1,"bidSize":11,"shortable":0,"etf":0,"ttmEps":-0.103,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1782091800000},"marketStatusCode":5,"adr":0,"adjPreClose":63.79,"symbolType":"stock","openAndCloseTimeList":[[1781746200000,1781753400000],[1781758800000,1781766000000]],"highLimit":70.17,"lowLimit":57.41,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":407937529,"isCdr":false,"pbRate":1.17,"roa":"--","roe":"1.25%","epsLYR":0.39,"committee":-0.304843,"marketValue":26149000000,"turnoverRate":0.017,"status":0,"floatMarketCap":25615000000},"requestUrl":"/m/hq/s/000661/tweets","defaultTab":"tweets","newsList":[{"id":"2645873015","title":"股市必读:长春高新(000661)6月18日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2645873015","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645873015?lang=zh_cn&edition=full","pubTime":"2026-06-22 02:35","pubTimestamp":1782066917,"startTime":"0","endTime":"0","summary":"截至2026年6月18日收盘,长春高新报收于64.1元,上涨0.49%,换手率1.7%,成交量6.81万手,成交额4.38亿元。董秘最新回复投资者: 股价持续下跌,公司高层没有解决方案吗?长春高新信用目前处于哪一个等级。当日关注点交易信息汇总:6月18日主力资金净流出1520.79万元,散户资金净流入1947.18万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062200000919.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000661","BK0057","BK0239","BK0028","BK0046","BK0188","BK0075"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645095479","title":"每周股票复盘:长春高新(000661)现1723.58万元大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2645095479","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645095479?lang=zh_cn&edition=full","pubTime":"2026-06-21 02:11","pubTimestamp":1781979070,"startTime":"0","endTime":"0","summary":"截至2026年6月18日收盘,长春高新(000661)报收于64.1元,较上周的66.5元下跌3.61%。本周,长春高新6月15日盘中最高价报66.39元。6月18日盘中最低价报63.01元,股价触及近一年最低点。长春高新当前最新总市值261.49亿元,在生物制品板块市值排名8/51,在两市A股市值排名834/5206。本周关注点交易信息汇总:6月15日长春高新现1723.58万元大宗交易交易信息汇总6月15日长春高新现1723.58万元大宗交易以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),仅供参考不构成投资建议。相关 ETF","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062100000541.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","BK0028","000661","BK0046","BK0057","BK0075"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644770797","title":"长春高新:结缔组织病相关间质性肺病相关适应症处于临床阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2644770797","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644770797?lang=zh_cn&edition=full","pubTime":"2026-06-18 15:18","pubTimestamp":1781767104,"startTime":"0","endTime":"0","summary":"证券之星消息,长春高新06月18日在投资者关系平台上答复投资者关心的问题。投资者提问:有研究证明,空气污染会引发一种名为白细胞介素-1β的信号分子的释放。当IL-1β到达携带休眠致癌突变的肺细胞时,会激活这些突变,细胞就会增殖并长成肿瘤,在暴露于空气污染的小鼠体内阻断IL-1β可阻止肿瘤形成,这为预防性药物的研发带来了希望。本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。相关 ETF责任编辑:沈彬","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061800020889.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","000661","BK0057","BK0028","BK0075","BK0046","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644762770","title":"长春高新:未发现存在违规变相协助大股东化债的情况","url":"https://stock-news.laohu8.com/highlight/detail?id=2644762770","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644762770?lang=zh_cn&edition=full","pubTime":"2026-06-18 15:18","pubTimestamp":1781767104,"startTime":"0","endTime":"0","summary":"证券之星消息,长春高新(000661)06月18日在投资者关系平台上答复投资者关心的问题。投资者提问:请问公司持续扩大支出资金几十亿,留给股东利润1.5个亿,请问巨额资金流向是否给实控人化债所用?长春高新回复:您好,上市公司与大股东之间有着严格的独立性要求,公司严格按照法律法规要求进行经营管理,严禁上市公司资金非经营性流向大股东。公司及会计师年审也会关注核验成本归集真实性及与大股东之间的资金往来情况,未发现存在违规变相协助大股东化债的情况。谢谢!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。相关 ETF责任编辑:沈彬","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061800020888.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000661","BK0046","BK0075","BK0188","BK0028","BK0057","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644702537","title":"长春高新:酒店项目于2025年6—7月相继正式开业运营","url":"https://stock-news.laohu8.com/highlight/detail?id=2644702537","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644702537?lang=zh_cn&edition=full","pubTime":"2026-06-18 15:12","pubTimestamp":1781766735,"startTime":"0","endTime":"0","summary":"证券之星消息,长春高新(000661)06月18日在投资者关系平台上答复投资者关心的问题。投资者提问:请问公司的投资十多亿的大酒店还在正常经营吗?长春高新回复:您好,酒店项目于2025年6—7月相继正式开业运营,并与洲际酒店集团专业管理团队合作,目前正常经营中,处于新开业初期的市场培育期,谢谢!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。相关 ETF责任编辑:陈思雨","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061800020792.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0075","000661","BK0188","BK0239","BK0057","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644770103","title":"长春高新:公司经营管理层努力提升经营质量","url":"https://stock-news.laohu8.com/highlight/detail?id=2644770103","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644770103?lang=zh_cn&edition=full","pubTime":"2026-06-18 15:06","pubTimestamp":1781766380,"startTime":"0","endTime":"0","summary":"证券之星消息,长春高新(000661)06月18日在投资者关系平台上答复投资者关心的问题。投资者提问:股价持续下跌,公司高层没有解决方案吗?长春高新回复:您好,公司经营管理层努力提升经营质量,加快产品研发、销售力度,希望以更好的业绩回报广大投资者。同时,公司未来若有达到信息披露要求的市值管理相关举措安排,将严格履行决策程序并及时对外披露。谢谢!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。相关 ETF责任编辑:沈彬","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061800020746.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0075","BK0046","000661","BK0239","BK0057","BK0188","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643527453","title":"6月15日长春高新现1723.58万元大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2643527453","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643527453?lang=zh_cn&edition=full","pubTime":"2026-06-15 17:40","pubTimestamp":1781516400,"startTime":"0","endTime":"0","summary":"证券之星消息,6月15日长春高新发生大宗交易,交易数据如下:近三个月该股共发生2笔大宗交易,合计成交2592.0手,溢价成交2笔。该股近期无解禁股上市。截至2026年6月15日收盘,长春高新(000661)报收于65.52元,下跌1.47%,换手率2.28%,成交量9.11万手,成交额5.96亿元。该股最近90天内共有7家机构给出评级,买入评级5家,增持评级2家;过去90天内机构目标均价为105.68。本文数据来源于深圳证券交易所大宗交易信息披露,仅供参考不构成投资建议。相关 ETF","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061500022413.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","BK0028","000661","BK0057","BK0075","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642637442","title":"长春高新最新公告:子公司注射用GenSci136获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2642637442","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642637442?lang=zh_cn&edition=full","pubTime":"2026-06-10 17:35","pubTimestamp":1781084157,"startTime":"0","endTime":"0","summary":"长春高新(000661.SZ)公告称,公司子公司金赛药业收到国家药监局核准签发的《药物临床试验批准通知书》,注射用GenSci136境内生产药品注册临床试验申请获批,适应症为眼肌型重症肌无力。该药品为金赛药业自主研发的BAFF/APRIL双靶点拮抗剂,属治疗用生物制品1类。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。相关 ETF","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061000031090.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","000661","BK0239","BK0188","BK0057","BK0046","BK0075"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642414009","title":"长春高新:系统性推进市值管理工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2642414009","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642414009?lang=zh_cn&edition=full","pubTime":"2026-06-10 11:35","pubTimestamp":1781062517,"startTime":"0","endTime":"0","summary":"董秘是否又在推动市值管理政策落地?长春高新回复:您好,公司充分重视市值管理工作,并持续通过强化核心竞争力、优化业务布局、完善投资者关系管理、进一步提升信息披露透明度等多方面举措,系统性地推进市值管理工作,致力于实现公司内在价值与市场价值的动态平衡,切实维护全体股东的长远利益。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061000017419.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000661","BK0239","BK0057","BK0028","BK0188","BK0046","BK0075"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642678416","title":"长春高新:公司全力聚焦医药创新与主业发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2642678416","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642678416?lang=zh_cn&edition=full","pubTime":"2026-06-10 08:57","pubTimestamp":1781053033,"startTime":"0","endTime":"0","summary":"证券之星消息,长春高新(000661)06月10日在投资者关系平台上答复投资者关心的问题。投资者提问:请问公司会尽快剥离房地产业务吗?长春高新回复:您好,感谢您对公司的关注,,公司全力聚焦医药创新与主业发展,同时也正推进辅业轻资产转型;同时,未来地产板块如有其他达到信息披露标准的情况,公司会按照法律法规要求履行披露义务,谢谢!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。相关 ETF","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061000007776.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","09939","000661","159938","BK0057","BK0239","BK1515","BK1161","BK0075","BK0028","BK0046","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642541662","title":"长春高新:产品临床试验获批相关公告是公司为了响应投资者所提出的希望公司持续提升信息披露透明度、增强投资者对于公司在研管线等情况了解的诉求进行的信息披露","url":"https://stock-news.laohu8.com/highlight/detail?id=2642541662","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642541662?lang=zh_cn&edition=full","pubTime":"2026-06-10 08:54","pubTimestamp":1781052851,"startTime":"0","endTime":"0","summary":"证券之星消息,长春高新06月10日在投资者关系平台上答复投资者关心的问题。产品临床试验获批相关公告是公司为了响应投资者所提出的希望公司持续提升信息披露透明度、增强投资者对于公司在研管线等情况了解的诉求进行的信息披露。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061000007740.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","000661","BK0239","BK0057","BK0028","BK0046","BK0075"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641668116","title":"长春高新:公司正处于从单一爆品向多元化创新的研发转型阵痛期","url":"https://stock-news.laohu8.com/highlight/detail?id=2641668116","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641668116?lang=zh_cn&edition=full","pubTime":"2026-06-05 16:42","pubTimestamp":1780648935,"startTime":"0","endTime":"0","summary":"证券之星消息,长春高新06月05日在投资者关系平台上答复投资者关心的问题。(长春高新回复:您好,创新药从临床、准入、学术推广到真正放量,普遍需要多年培育期,必须持续投入才能形成壁垒。目前公司正处于从单一爆品向多元化创新的研发转型阵痛期,我们希望随着相关创新药后续逐步落地,能够使公司收获更多的研发成果,我们也将持续关注研发进展及费用支出情况,努力提升研发效率等。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060500028386.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000661","BK0188","BK0075","BK0057","BK0028","BK0239","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641194819","title":"长春高新:公司此前向港交所提交的 H 股发行上市申请材料(A1 申请表)已超过港交所规定的六个月申报有效期","url":"https://stock-news.laohu8.com/highlight/detail?id=2641194819","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641194819?lang=zh_cn&edition=full","pubTime":"2026-06-05 11:39","pubTimestamp":1780630764,"startTime":"0","endTime":"0","summary":"证券之星消息,长春高新(000661)06月05日在投资者关系平台上答复投资者关心的问题。投资者提问:请问公司去年计划在港交所上市,目前是什么情况呢?是计划已经取消,还是在持续推进?长春高新回复:您好,公司此前向港交所提交的 H 股发行上市申请材料(A1 申请表)已超过港交所规定的六个月申报有效期。公司将结合自身经营状况、监管政策要求及市场投资者关切,审慎、合理推进后续相关工作,具体时间需要结合工作进度和监管部门审核情况。谢谢!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。相关 ETF","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060500015594.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0046","HEXmain","BK0075","BK0239","BK0028","000661","BK0057"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641194848","title":"长春高新:公司长期坚持合规为先的营销管理原则","url":"https://stock-news.laohu8.com/highlight/detail?id=2641194848","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641194848?lang=zh_cn&edition=full","pubTime":"2026-06-05 11:39","pubTimestamp":1780630759,"startTime":"0","endTime":"0","summary":"证券之星消息,长春高新06月05日在投资者关系平台上答复投资者关心的问题。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060500015591.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0057","BK0239","000661","BK0075","BK0188","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640582150","title":"长春高新:相关股东自持有公司股份以来并未减持过公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2640582150","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640582150?lang=zh_cn&edition=full","pubTime":"2026-06-04 20:48","pubTimestamp":1780577315,"startTime":"0","endTime":"0","summary":"证券之星消息,长春高新(000661)06月03日在投资者关系平台上答复投资者关心的问题。投资者提问:目前投资者都在担忧王思勉女士后续减持问题,请问公司如何打消投资者顾虑?长春高新回复:您好,相关股东自持有公司股份以来并未减持过公司股份;同时根据监管要求,上市公司持有百分之五以上股份的股东计划通过证券交易所集中竞价交易或者大宗交易方式减持股份的,应当在首次卖出前十五个交易日向证券交易所报告并披露减持计划;截至目前,公司未收到股东的减持计划通知。谢谢!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。相关 ETF","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060400039301.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0057","BK0239","BK0075","BK0188","BK0028","000661"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640391611","title":"长春高新:公司管理团队涵盖医药、企管、财务、法务、金融等多元专业背景","url":"https://stock-news.laohu8.com/highlight/detail?id=2640391611","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640391611?lang=zh_cn&edition=full","pubTime":"2026-06-04 11:35","pubTimestamp":1780544129,"startTime":"0","endTime":"0","summary":"证券之星消息,长春高新(000661)06月04日在投资者关系平台上答复投资者关心的问题。投资者提问:请问公司管理层90%都是地产行业出身,缺少专业性,这是否也导致了公司研发销售管理效率全行业最低?长春高新回复:您好,相关表述与实际不符。公司管理团队涵盖医药、企管、财务、法务、金融等多元专业背景,各医药子公司经营、研发核心团队汇聚大批深耕生物医药领域的专业人才,适配整体经营管理需求,谢谢!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。相关 ETF","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060400014462.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK1574","BK1161","BK1515","000661","BK0075","BK0239","159938","BK0057","BK0046","159940","09939","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640139917","title":"长春高新:公司相关费用的投入本质都是构建多元管线的必要投资","url":"https://stock-news.laohu8.com/highlight/detail?id=2640139917","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640139917?lang=zh_cn&edition=full","pubTime":"2026-06-04 11:35","pubTimestamp":1780544120,"startTime":"0","endTime":"0","summary":"证券之星消息,长春高新06月04日在投资者关系平台上答复投资者关心的问题。公司相关费用的投入本质都是构建多元管线的必要投资,细分包括员工薪酬、差旅、会议、推广投入等,具体费用明细请参见定期报告第八节中销售费用明细相关内容。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060400014457.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","000661","BK0188","BK0057","BK0046","BK0075"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640133992","title":"长春高新:研发资金主要投向技术平台建设、临床阶段产品开发、早期管线布局等核心方向","url":"https://stock-news.laohu8.com/highlight/detail?id=2640133992","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640133992?lang=zh_cn&edition=full","pubTime":"2026-06-04 09:12","pubTimestamp":1780535536,"startTime":"0","endTime":"0","summary":"证券之星消息,长春高新06月04日在投资者关系平台上答复投资者关心的问题。研发资金主要投向技术平台建设、临床阶段产品开发、早期管线布局等核心方向。公司已建立全流程研发费用管控、决策机制和内控体系,努力保障每一笔研发资金合理、合规使用。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060400005505.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000661","BK0188","BK0075","BK0057","BK0028","BK0239","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640133647","title":"长春高新:研发持续落地多款新药、核心产品市占率领先","url":"https://stock-news.laohu8.com/highlight/detail?id=2640133647","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640133647?lang=zh_cn&edition=full","pubTime":"2026-06-04 09:09","pubTimestamp":1780535373,"startTime":"0","endTime":"0","summary":"证券之星消息,长春高新(000661)06月04日在投资者关系平台上答复投资者关心的问题。投资者提问:公司研发、销售、管理方面的能力什么时候能够达到专业医药公司的水平?目前公司的研发销售管理完全就是一个业余水平,投入巨大,毫无成效。 这种状况何时能够改善?长春高新回复:您好,公司深耕生物医药多年,研发持续落地多款新药、核心产品市占率领先,搭建完备研产销体系。目前正努力克服政策及行业变化影响,持续优化投入效率与内部管理,稳步提质增效,公司也希望相关改善成效随项目落地逐步体现。谢谢!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。相关 ETF","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060400005292.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0057","000661","BK0188","BK0239","BK0075","BK0046","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640890809","title":"长春高新(000661.SZ)子公司GenSci155注射液境内生产药品注册临床试验申请获得批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2640890809","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640890809?lang=zh_cn&edition=full","pubTime":"2026-06-03 17:53","pubTimestamp":1780480433,"startTime":"0","endTime":"0","summary":"智通财经APP讯,长春高新(000661.SZ)发布公告,近日,公司子公司长春金赛药业有限责任公司(简称“金赛药业”)收到国家药品监督管理局核准签发的《药物临床试验批准通知书》,金赛药业GenSci155注射液境内生产药品注册临床试验申请获得批准。GenSci155注射液是金赛药业自主研发的一款长效化脂肪酸偶联重组人胰岛素样生长因子-1(IGF-1)类似物,注册分类为治疗用生物制品1类,拟用于预防早产儿支气管肺发育不良(BPD)、急性缺血性卒中(AIS)。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1449661.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"长春高新(000661.SZ)子公司GenSci155注射液境内生产药品注册临床试验申请获得批准","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","000661","BK0239","BK0028","BK0075","BK0057","BK0046"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1782075382113,"stockEarnings":[{"period":"1week","weight":-0.0034},{"period":"1month","weight":-0.2297},{"period":"3month","weight":-0.269},{"period":"6month","weight":-0.3308},{"period":"1year","weight":-0.362},{"period":"ytd","weight":-0.306}],"compareEarnings":[{"period":"1week","weight":0.026},{"period":"1month","weight":-0.019},{"period":"3month","weight":0.0337},{"period":"6month","weight":0.0514},{"period":"1year","weight":0.2071},{"period":"ytd","weight":0.0306}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"长春高新技术产业(集团)股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"138133人(较上一季度增加7.70%)","perCapita":"2892股","listingDate":"1996-12-18","address":"吉林省长春市朝阳区高新区海容酒店及海茵广场写字楼B座2708室","registeredCapital":"40793万元","survey":" 长春高新技术产业(集团)股份有限公司的主营业务是生物制药及中成药的研发、生产和销售。公司的主要产品是注射用人生长激素、重组人生长激素注射液、注射用重组人促卵泡激素、重组人促卵泡激素注射液、醋酸曲普瑞林注射液、伏欣奇拜单抗、屋尘螨变应原制剂、醋酸甲地孕酮口服混悬液、口腔凝胶、水痘减毒活疫苗、带状疱疹减毒活疫苗、冻干鼻喷流感减毒活疫苗、鼻喷流感减毒活疫苗、银花泌炎灵片、清胃止痛微丸、血栓心脉宁片、疏清颗粒。","listedPrice":8.8},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"长春高新(000661)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供长春高新(000661)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"长春高新,000661,长春高新股票,长春高新股票老虎,长春高新股票老虎国际,长春高新行情,长春高新股票行情,长春高新股价,长春高新股市,长春高新股票价格,长春高新股票交易,长春高新股票购买,长春高新股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"长春高新(000661)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供长春高新(000661)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}